anxiety disorders pathological fear
Conditions
Interventions
The primary intervention consists of one oral intake of a capsule with 300 mg
cannabidiol or placebo.
Sponsors
Universiteit Utrecht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: - Male or female volunteers between 18 and 30 years. - Judged to be in good physical and mental health on the basis of the medical history according to self-report. - Have a normal binocular acuity, corrected or uncorrected. - Female participants must declare they are on reliable birth control.
Exclusion criteria
Exclusion criteria: - History of any disease, e.g. neurological disorders, psychiatric disorders, which in the opinion of the investigator may confound the results of the study. - Present any other conditions in that in the investigators*, the subjects* personal or the study physicians* opinion may confound the results of the study. - History of psychotic disorder/psychosis and/or having a first/second degree family member with (a history of) psychotic disorder/psychosis. - Current diagnosis of an Axis I or Axis II psychiatric disorder, or suffering from an Axis I or Axis II psychiatric disorder within 4 weeks prior to the study. - Current cardiac disease and/or history of cardiac disease. - Known hypersensitivity to CBD. - History of cannabinoids exopsure with adverse reactions. - History of severe allergy or general drug hypersensitivity. - History of abuse or current regular use of cannabis more than once a week. - Usage of psychoactive drugs in the four weeks prior to the study. - Current use of drugs of abuse or indications (urine screening) - History of epilepsy. - Pregnancy, i.e., a positive *-HCG urine test. - Lactating. - Reduced startle reactivity, defined as no discernable response in at least 3 out of the 12 startle stimuli presented at screening.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fear as reflected in the EMG and SCR amplitude and as reflected in answers on a VAS during a passive VR navigation task (see protocol [C1] for details). | — |
Countries
Netherlands
Outcome results
None listed